Linda Hayes Bennett on The Terrain-Level Determinants of Ischemic Stroke
Linda Hayes Bennett, Cognitive-Behavioral Neuroscientist, shared on LinkedIn:
”Abstract: The Terrain-Level Determinants of Ischemic Stroke — An ALH–eGFR Framework for Precision Prevention
While ischemic stroke is classically categorized by mechanism—embolism, thrombosis, dissection, or small-vessel disease—these visible outcomes emerge from deeper, measurable changes in the body’s terrain.
In this integrated framework, stroke risk is redefined not as an isolated vascular event but as the endpoint of cumulative terrain erosion.
Declining eGFR (estimated glomerular filtration rate), endothelial microinjury, oxidative stress, dehydration, and allostatic overload together alter plasma viscosity, shear dynamics, and mitochondrial resilience—conditions that silently prepare the vasculature for failure.
Likewise, caregiving stress, malnutrition, and iatrogenic medication patterns accelerate inflammatory cascades and vascular fragility.
The ALH Caregiver Index, paired with eGFR trajectories, identifies early inflection points where preventive interventions—hydration, oxygenation, rhythm regulation, cooling therapy, and caregiver education—can preserve neuronal integrity and reduce stroke incidence.
This terrain-based model reframes prevention around upstream metrics of biological and behavioral health, bridging patient care, public health, and precision medicine.”
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Mar 11, 2026, 18:27Cesar Garrido and Lackram Bodoe Are Advancing WFH Partnerships in Trinidad and Tobago
-
Mar 11, 2026, 18:14Aloke Finn: Silent Plaque Rupture and Healing in Coronary Artery Disease
-
Mar 11, 2026, 17:23Mattia Galli: A Privilege to Collaborate on Such a Complex Topic as Cardio-Rheumatology
-
Mar 11, 2026, 17:12Shubham Misra: Proteomic Biomarkers for Acute Stroke Subtype Classification
-
Mar 11, 2026, 16:55Melanie Daniel: Modeling High-Purity von Willebrand Factor for Individualized Dosing in Surgery
-
Mar 11, 2026, 15:46Bleeding and Thrombosis Outcomes in Older Patients With Myelodysplastic Syndromes – JTH
-
Mar 11, 2026, 15:37Sonia Muliyil: The Greatest Benefit is The Wellbeing and Sustenance of Half The World’s Population
-
Mar 11, 2026, 15:34Kymentie Ferdinande: Rivaroxaban in Cirrhosis and the Path Toward Individualized Anticoagulation
-
Mar 11, 2026, 15:34Sheharyar Raza: When More Testing Isn’t Always Better in Healthy Donor Screening